BAC to collaborate with sanofi pasteur on vaccine purification

Published: 2-May-2007
Manufacturing Ingredients Pharmaceutical

Dutch company BAC (Bio Affinity Company) has entered into a collaboration agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group.


Dutch company BAC (Bio Affinity Company) has entered into a collaboration agreement with sanofi pasteur, the vaccines business of the sanofi-aventis Group.

BAC's CaptureSelect customised affinity ligands have been selected by sanofi pasteur as they potentially offer high stability and specificity for process-scale purification of some of its vaccine products.

Manufactured using a high-yielding proprietary animal-free, yeast-based expression system, CaptureSelect ligands exploit the nature of Camelid single chain antibody fragments and offer enhanced stability and broad antigen-specific binding compared to traditional affinity media.

'This is a significant collaboration for BAC,' said Dr Laurens Sierkstra, ceo of BAC. 'This latest agreement further endorses the suitability of our CaptureSelect technology for commercial-scale bioprocessing.'

See more

You may also like

Manufacturing

CPI collaborates with industry leaders to expedite drug manufacturing via digitisation

Read more
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  3. ChargePoint invest in a single-use manufacturing facility to expand product line The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
  4. Licensing and supply agreement for voretigene neparvovec outside the US Spark Therapeutics announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialise investigational voretigene neparvovec outside the US, while Spark Therapeutics will continue to exclusively commercialise Luxturna (voretigene neparvovec-ryzl) in the US

Upcoming event

ASGCT Annual Meeting 2024

7-11 May, 2024 | Meeting | Portland, OR See all

You may also like

Manufacturing

CPI collaborates with industry leaders to expedite drug manufacturing via digitisation

Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Marketing

Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation

The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Manufacturing

Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide

CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
Regulatory

Tivdak receives US FDA approval for treating recurrent cervical cancer

The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy
Manufacturing

Marchesini Group at Achema 2024: celebrating 50 years of innovation

At G3, Hall 3.1, the Marchesini Group will exhibit pharmaceutical manufacturing machines, packaging solutions and digital tools to enhance manufacturing processes
Manufacturing

US court lifts modified consent decree on Xellia’s Cleveland facility

The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Manufacturing

Miltenyi Biotec and MiLaboratories collaborate to advance next-generation therapies

Miltenyi Biotec will commercialise MiLaboratories' RNA kit technology for immune sequencing, facilitating advances in the field of personalised medicine
Subscribe now